Hark Kyun Kim

6PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 12, 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.

Yoon-Koo Kang, Hyung-Don Kim, Jeong Hwan Yook

|Apr 15, 2022
A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines.

Sang Soo Eom, Wonyoung Choi, Bang Wool Eom

|Mar 11, 2022
Smad4 and p53 synergize in suppressing autochthonous intestinal cancer.

Jun Won Park, Min-Jung Seo, Kye Soo Cho

|Jun 16, 2021
PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.

Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park

|Apr 14, 2021
MiR-30a and miR-200c differentiate cholangiocarcinomas from gastrointestinal cancer liver metastases.

Jun Won Park, Jong Min Jeong, Kye Soo Cho

|Mar 13, 2020
Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors.

Hark Kyun Kim, Jeong Won Kang, Young-Whan Park

Pageof 1

Frequent Collaborators

3 joint publications

Myeong-Cherl Kook

2 joint publications

Sung Hoon Noh

2 joint publications

Baek-Yeol Ryoo

2 joint publications

Yoon-Koo Kang